Bucelon 2 Busulfan Tablets myleran

[Product Name] Busulfan Tablets

[English Name] Busulfan Tablets

[Specification] 2 mg × 25 tablets/box

[Manufacturer] Celon Laboratories Ltd

[Indications] Used for chronic myeloid leukemia; also effective for polycythemia vera, chronic lymphocytic leukemia, and lymphoma.

[Dosage and Administration] Chronic Myeloid Leukemia: Adults—Remission Induction: 60 µg/kg/day (maximum dose: 4 mg/day), administered as a single dose. Maintenance Therapy: The dose is typically 500 µg to 2 mg/day. Polycythemia Vera and Primary Thrombocythemia—Remission Induction: 4–6 mg/day. Maintenance Therapy: The dose is approximately half of the induction dose. Myelofibrosis: Initial dose is 2–4 mg/day.

[Adverse Reactions] Gastrointestinal reactions are generally mild. The primary adverse effects are bone marrow suppression, thrombocytopenia, and hemorrhagic symptoms. Prolonged use may lead to bone marrow aplasia. Additionally, symptoms such as dizziness, facial flushing, cold extremities, brownish-red skin pigmentation, alopecia, and skin rashes may occur. Occasionally, it may cause testicular atrophy and gynecomastia in men, and amenorrhea in women. In isolated cases, long-term use may lead to pulmonary fibrosis and adrenocortical insufficiency.

[Contraindications]

1. Contraindicated in patients with acute leukemia, aplastic anemia, or other hemorrhagic disorders.

2. Use with caution in patients with adrenocortical insufficiency. 3. Use with caution or avoid use in pregnant women.

[Precautions] This medication should not be used in patients who have recently undergone radiotherapy or treatment with other cytotoxic drugs. Use with caution in pregnant women. Treatment should be discontinued if chronic myeloid leukemia undergoes acute transformation. Blood counts must be strictly monitored during the course of treatment.

[Precautions for Pregnancy and Lactation]

This medication should not be taken by pregnant or breastfeeding women.

[Precautions for the Elderly] Not yet established.

[Drug Interactions] Since the use of this product may increase uric acid levels in the blood and urine, anti-gout medications may be administered to patients with a history of gout or to those who experience elevated uric acid levels following treatment with this product. [Pharmacological Action] This agent belongs to the class of bifunctional alkylating agents known as dimethylsulfonates and acts as a cell-cycle non-specific drug. Upon entering the human body, the cyclic structure of the sulfonate groups opens; the drug then disrupts the structure and function of cellular DNA by alkylating guanine residues within the DNA strands. The cytotoxic effects of this product are manifested almost exclusively as the suppression of hematopoietic function, primarily characterized by a marked inhibitory effect on granulopoiesis. Secondary effects include the suppression of platelet and erythrocyte production, while its inhibitory effect on lymphocytes is very weak.

[Storage] Store at room temperature; protect from light; keep tightly sealed.

Product Specifications

Product Name: Busulfan Tablets 2 mg × 25 Tablets/Box (Bucelon 2) | Synonyms: Busulfan, Myleran

Common Name: Busulfan Tablets

Composition: Busulfan

Dosage Form: Tablets

Specification: 2 mg × 25 tablets/box

Manufacturer: Celon Laboratories Ltd

Indications: Used for the treatment of Chronic Myeloid Leukemia (CML); also effective in cases of Polycythemia Vera, Chronic Lymphocytic Leukemia (CLL), and Lymphoma.

Dosage and Administration:Chronic Myeloid Leukemia (Adults)—Induction of Remission: 60 µg/kg/day (maximum dose: 4 mg/day), administered as a single daily dose. Maintenance Therapy: The dosage is typically 500 µg to 2 mg/day. Polycythemia Vera and Primary Thrombocythemia—Induction of Remission: 4–6 mg/day. Maintenance Therapy: The dosage is approximately half of the induction dose. Myelofibrosis: Initial dosage is 2–4 mg/day.